Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
adding, AIM, assist, biopharmaceutical, British, category, China, Circassia, Clarifying, Codification, compassionate, correct, correction, depreciation, dividing, equipmentare, error, exceed, experience, FASBissuedAccounting, front, hold, hospital, InJanuary, insured, intangible, Kingdom, light, London, lose, met, objective, ongoing, partner, pharmaceutical, plc, predetermined, presence, Reclassification, reclassified, retrospective, retrospectively, sound, specialty, Supplemental, trial, widely
Filing tables
Filing exhibits
Related press release
XAIR similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION
In connection with the accompanying Quarterly Report on Form 10-Q of AIT Therapeutics, Inc. for the period ended December 31, 2018 (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:
(1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of AIT Therapeutics, Inc. |
/s/ Douglas Beck | |
Douglas Beck Chief Financial Officer | |
(Principal Financial and Accounting Officer) |
February 14, 2019
The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes—Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document of AIT Therapeutics, Inc. or the certifying officers.